Cellosaurus ST486 (CVCL_1712)

Cell line name ST486
Synonyms ST 486
Accession CVCL_1712
Resource Identification Initiative To cite this cell line use: ST486 (RRID:CVCL_1712)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MYC genetic alteration cell panel (ATCC TCP-1035).
Characteristics: EBV-negative.
Doubling time: 19-20 hours (ATCC).
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: TP53 p.Arg158His (PubMed=2052620; PubMed=8344493).
Omics: Deep exome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Omics: Virome analysis using RNAseq.
Disease Burkitt lymphoma (NCIt: C2912)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP

Markers:
AmelogeninX
CSF1PO10,12
D13S3178,12
D16S5399,12
D5S81811,12
D7S8207,12
TH017,9
TPOX8,11
vWA17,18
Publications

PubMed=6243721; DOI=10.1093/jnci/64.3.465
Magrath I.T., Pizzo P.A., Whang-Peng J., Douglass E.C., Alabaster O., Gerber P., Freeman C.B., Novikovs L.
Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. I Physical, cytogenetic, and growth characteristics.
J. Natl. Cancer Inst. 64:465-476(1980)

PubMed=6243722; DOI=10.1093/jnci/64.3.477
Magrath I.T., Freeman C.B., Pizzo P.A., Gadek J., Jaffe E., Santaella M., Hammer C., Frank M., Reaman G., Novikovs L.
Characterization of lymphoma-derived cell lines: comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen II. Surface markers.
J. Natl. Cancer Inst. 64:477-483(1980)

PubMed=6265077
Pizzo P.A., Chattopadhyay S.K., Magrath I.T., Del Giacco E., Sherrick D., Gray T.
Examination of Epstein-Barr virus and C-type proviral sequences in American and African lymphomas and derivative cell lines.
Cancer Res. 41:3165-3171(1981)

PubMed=6286763
Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D., Parsons R.G.
Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type.
J. Immunol. 129:1336-1342(1982)

PubMed=6328505; DOI=10.1073/pnas.81.10.3170
Croce C.M., Erikson J., ar-Rushdi A., Aden D., Nishikura K.
Translocated c-myc oncogene of Burkitt lymphoma is transcribed in plasma cells and repressed in lymphoblastoid cells.
Proc. Natl. Acad. Sci. U.S.A. 81:3170-3174(1984)

PubMed=3080238
Sieverts H., Alabaster O., Goldschmidts W., Magrath I.T.
Expression of surface antigens during the cell cycle in different growth phases of American and African Burkitt's lymphoma cell lines.
Cancer Res. 46:1182-1188(1986)

PubMed=2052620; DOI=10.1073/pnas.88.12.5413
Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W., Magrath I.T., Knowles D.M., Dalla-Favera R.
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.
Proc. Natl. Acad. Sci. U.S.A. 88:5413-5417(1991)

PubMed=1325212
Benjamin D., Knobloch T.J., Dayton M.A.
Human B-cell interleukin-10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt's lymphoma constitutively secrete large quantities of interleukin-10.
Blood 80:1289-1298(1992)

PubMed=8344493
Bhatia K., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R., Magrath I.T.
Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect.
FASEB J. 7:951-956(1993)

PubMed=8515068
Jain V.K., Judde J.-G., Max E.E., Magrath I.T.
Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
J. Immunol. 150:5418-5428(1993)

PubMed=7757991
Bae I., Fan S., Bhatia K., Kohn K.W., Fornace A.J. Jr., O'Connor P.M.
Relationships between G1 arrest and stability of the p53 and p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma cells.
Cancer Res. 55:2387-2393(1995)

PubMed=9473234
Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.
p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma.
Blood 91:1680-1687(1998)

PubMed=9973220
Gutierrez M.I., Cherney B., Hussain A., Mostowski H., Tosato G., Magrath I.T., Bhatia K.
Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis.
Cancer Res. 59:696-703(1999)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25355872; DOI=10.1128/JVI.02570-14
Cao S., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z., O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.
High-throughput RNA sequencing-based virome analysis of 50 lymphoma cell lines from the Cancer Cell Line Encyclopedia project.
J. Virol. 89:713-729(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections ATCC; CRL-1647
Cell line databases/resources CCLE; ST486_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
Cosmic-CLP; 910906
GDSC; 910906
IGRhCellID; ST486
LINCS_LDP; LCL-2026
Ontologies CLO; CLO_0009143
EFO; EFO_0002353
Biological sample resources BioSample; SAMN03471412
Chemistry resources ChEMBL-Cells; CHEMBL3308887
ChEMBL-Targets; CHEMBL2366293
Gene expression databases GEO; GSM887649
GEO; GSM888741
GEO; GSM1670480
Polymorphism and mutation databases Cosmic; 687853
Cosmic; 910906
Cosmic; 931134